Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.
Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G, Jing X, Beri N, Khanna L, Gonda T, Oberstein P, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsirigos A, Simeone DM. · 2023
Read Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. by Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G, Jing X, Beri N, Khanna L, Gonda T, Oberstein P, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsirigos A, Simeone DM. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9925748.txt.
Introduction
Werba and co-authors use single-cell RNA sequencing to study chemotherapy effects in pancreatic cancer. Pancreatic ductal adenocarcinoma has a complex tumor setting that drives growth. Deep single-cell work on how that setting responds to therapy was lacking. The team sampled fresh human tumors before and after chemotherapy.
Samples held a mix of basal and classical cancer cell types. They also held distinct fibroblast and macrophage groups. Both cancer types responded to chemotherapy in like ways, with no shift toward a basal program. Cell-to-cell signals fell after treatment, notably TIGIT signals to cancer cells. TIGIT stood out as the main inhibitory checkpoint on CD8 T cells. The authors warn that chemotherapy may aid resistance to immunotherapy.
Catalog record
| CREATOR | Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G, Jing X, Beri N, Khanna L, Gonda T, Oberstein P, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsirigos A, Simeone DM. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment By Gregor Werba, Daniel Weissinger, Emily A Kawaler, Ende Zhao, Despoina Kalfakakou, Surajit Dhara, Lidong Wang, Heather B Lim, Grace Oh, Xiaohong Jing, Nina Beri, Lauren Khanna Published in: Nature Communications DOI: 10.1038/s41467-023-36296-4 ABSTRACT Abstract The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a complex ecosystem that drives tumor progression; however, in-depth single cell characterization of the PDAC TME and its role in response to therapy is lacking. Here, we perform single-cell RNA sequencing on freshly collected human PDAC samples either before or after chemotherapy. Overall, we find a heterogeneous mixture of basal and classical cancer cell subtypes, along with distinct cancer-associated fibroblast and macrophage subpopulations. Strikingly, classical and basal-like cancer cells exhibit similar transcriptional responses to chemotherapy and do not demonstrate a shift towards a basal-like transcriptional program among treated samples. We observe decreased ligand-receptor interactions in treated samples, particularly between TIGIT on CD8 + T cells and its receptor on cancer cells, and identify TIGIT as the major inhibitory checkpoint molecule of CD8 + T cells. Our results suggest that chemotherapy profoundly impacts the PDAC TME and may promote resistance to immunotherapy. Subject terms: Pancreatic cancer, Cancer microenvironment, Pancreatic cancer, Bioinformatics, Cancer microenvironment INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of approximately 11%1. With increasing incidence, it is projected to become the second leading cause of cancer-related deaths in the United States by 20302. Current treatment options are limited. Only 15% to 20% of patients qualify for upfront surgery with curative intent; the remaining patients present with unresectable locally advanced disease or distant metastases. Nearly all patients receive adjuvant, neoadjuvant, or palliative chemotherapy3. Recent advances in immunomodulating drugs, such as checkpoint inhibitors, have yet to show encouraging results in PDAC4,5. A deeper understanding of pancreatic cancer biology is needed to develop better therapeutics and improve outcomes. Although recent genomic and transcriptomic studies on bulk tumor samples identified key molecular drivers (notably KRAS, TP53, CDKN2A, and SMAD4) and cancer cell subtypes (basal and classical), these findings have yet to translate into treatment advances6–9. Recent investigations into the PDAC tumor microenvironment (TME) revealed that this complex ecosystem is a critical mediator of therapeutic resistance and tumor progression10,11. Single-cell RNA sequencing (scRNA-seq) has emerged as a valuable tool in precision medicine by enabling in-depth characterization of the TME and serial assessment on scant amounts of tissue12–17. While recent single-cell studies have provided insights into PDAC, there is an unmet need to characterize the effects of chemotherapy on the TME18–22. For a comprehensive view of the PDAC TME, and its response to chemotherapy in a real-time clinical context, here we perform scRNA-seq on freshly collected tumor specimens from 27 PDAC patients. We observe significant heterogeneity in the malignant epithelial compartment, with most tumors displaying a mixture of basal-like and classical-like cells. Furthermore, we examine the composition of CAFs and discrete groups of immune cells in the TME and execute comparative analyses on naive and chemotherapy-treated samples, which we confirm in an external dataset. Our data show that chemotherapy profoundly alters the PDAC TME, inducing features consistent with tumor progression and refractoriness to immunotherapy by downregulation of inhibitory checkpoint molecules in CD8 + T cells. RESULTS Single-cell analysis reveals the transcriptomic landscape in PDAC PDAC specimens were acquired via surgical resection of primary pancreatic lesions (n = 10) or by endoscopic/interventional radiology–guided biopsies of either primary pancreatic lesions (n = 7) or liver metastases (n = 10) (Fig. 1A, Supplementary Table 1). Of the 27 total patients, seven received chemotherapy (FOLFIRINOX-based n = 4, gemcitabine/abraxane-based n = 3) prior to tissue collection, while 20 patients had not been treated at the time of specimen acquisition (Fig. 1A, Supplementary Table 1). Evaluating the treated patients using the RECIST criteria, we found that two had stable disease, two partial response, three progressive disease, and one was nonevaluable (Supplementary Table 2). We prepared single-cell suspensions from tumor specimens and sequenced them using the 10x Genomics Chromium system (Fig. 1B, see Methods for details). Histopathological assessment was done on each tumor specimen to verify malignancy, and samples underwent mutational profiling (Supplementary Data 1, 2). After standard processing and quality filtering of the raw sequencing data (see Methods), a total of 139,446 cells were retained for analysis. Unsupervised, graph-based clustering and visualization via uniform manifold approximation and projection (UMAP) revealed ten distinct cell clusters that were annotated using canonical markers and gene expression profiles (Fig. 1C, D, Supplimentary Fig. 1A, Methods). Three major clusters were identified as epithelial, T/natural killer (NK), and myeloid cells. We further identified CAFs, endothelial cells, B/plasma cells, and a small mast cell population among our clusters. The proportional distribution of these major cell types was similar across all groups, with the exception of biopsies from liver metastases and primary PDAC which had quantitatively lower CAFs and endothelial cells than resection samples. We also identified an elevated amount of proliferating cancer cells in liver biopsies (Fig. 1E; Supplementary Fig. 1B). To ensure that tissue processing did not significantly change gene expression in our samples, we applied hypoxia and dissociation signatures23,24 to our dataset. This analysis showed that all scSeq samples contained very few hypoxic cells, with no significant differences between procedures (Supplimentary Fig. 1C), and demonstrated low dissociation signatures independent of procedure (Supplimentary Fig. 1D). [Figure: Single-cell analysis reveals the transcriptomic landscape in PDAC.A Clinicopathologic characteristics for each patient sample including treatment status, stage, Moffitt subtype, and procedure. EUS endoscopic ultrasound. B Workflow depicting sample acquisition, processing, and analysis. Designed with BioRender©. C UMAP, embedding of the expression profile of 139,446 cells that passed quality control from n = 27 patient samples. Distinct clusters are annotated and color-coded. CAF cancer-associated fibroblast, NK natural killer, UMAP uniform manifold approximation and projection. D Heatmap of the five most differentially expressed genes within each cluster. Colors correspond to the cluster colors in Fig. 1C. E Proportional distribution of each cell cluster by individual sample.] The epithelial compartment reveals heterogeneous malignant subtype composition The epithelial compartment evinced sample-specific differences while the mesenchymal and immune compartments clustered together across all samples (Supplimentary Fig. 2A). This suggests that non-epithelial cells of the PDAC TME share more common transcriptional signatures across all patients than their malignant counterparts within the same tumor. Since some epithelial cells also clustered across samples, we further assessed the proportion of malignant cells in the total epithelial compartment (Fig. 2A). To this end, we performed copy number variation (CNV) analysis. The vast majority of epithelial cells showed several CNV events, indicating malignancy and distinguishing them from normal epithelial cells (Fig. 2B, Supplimentary Fig. 2B). We further classified malignant cells as either basal or classical based on their Moffitt subtype signature expression7. (Any signature gene sets referenced in this paper can be found in Supplimentary Data 3). All samples but one were comprised of a mixture of basal and classical cancer cells in varying proportions (Fig. 2C, D). Tumor subtype composition did not correlate with the amount of any major non-malignant cell types (Supplimentary Fig. 2C). [Figure: The epithelial compartment reveals heterogeneous malignant subtype composition.A Non-batch corrected UMAP of all epithelial cells,